Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality. We do this through our proven brand and sales know-how, strong expertise across a number of key therapeutic categories, and deep experience in all critical Asia Pacific countries. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.

With more than 3,500 employees throughout Asia Pacific, Invida operates throughout the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands as well as licensed products from biotech and multinational companies. Partnering is a critical component of Invida’s business model.

Invida operates in the fastest growing healthcare markets worldwide, increasing at an annual compounded growth rate of 12 percent, more than double the global growth rate for the sector. Today, the Asia Pacific markets represent approximately US$50 billion and 10 percent of worldwide pharmaceutical sales.* With China and India among top growth contributors globally, Invida is currently implementing a long-term strategy to establish itself as a leader in these rapidly expanding markets through targeted investments.

As multinational pharmaceutical companies re-prioritize portfolios and others seek experienced, trusted partners to enter large and emerging markets, Invida provides the option of a single reliable partner in the Asia Pacific markets.

History

Invida was formed in 2005 by a powerful strategic partnership of Quintiles, the world’s leading pharmaceutical services organization; Temasek Holdings, one of the world’s largest investment companies, and Zuellig Group, the largest pharmaceutical distribution and supply chain management network in Asia Pacific.

On 11 November 2011, Italy based Menarini Group successfully bid and acquired Invida Group, a strategic move that is poised to allow both companies and its partners to have a stronger presence in the Asia Pacific region. With 17,000 employees and annual revenue exceeding USD4.4 Billion, Menarini is the largest Italian pharmaceutical group and ranks 34^th of 14,051 pharmaceutical companies in the world.

Invida carries with it the history, relationships and strong track record with its global partners. 

*source: McKinsey & Company